Thyroid Hormone Action, Metabolism, and Regulation Presentations at American Thyroid Association: 89th Annual Meeting

The American Thyroid Association will hold its 89th Annual Meeting on October 30-November 3, 2019, at the Sheraton Grand Chicago in Chicago, Illinois. In addition to hearing major speeches and awards, attendees can view the following oral presentations on thyroid hormone action, metabolism, and regulation.

  1. Dr. Xi Ding, of the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China, will give a presentation, “Low Serum Free Thyroxine Levels Are Associated with Metabolic Syndrome in a Euthyroid Health Population: A Retrospective Cohort Study in Shaanxi Province, China” (Oral 14), on Thursday, October 31, 2019. Previous studies have shown an association between thyroid hormones and metabolic syndrome. However, these studies were cross-sectional, and results have been controversial. Mr. Ding and his colleagues assessed correlations between metabolic syndrome and various thyroid hormones in 1,627 euthyroid participants. They identified a threshold for serum free thyroxine and found that a level below that threshold is an independent risk factor for developing metabolic syndrome.
  2. Dr. Sarah Peterson, of Rush University Medical Center, Chicago, Illinois, will give a presentation, “Effect of Thr92Ala-DIO2 Polymorphism on Cognition, Mood, and Health Status Among LT4 Treated Hypothyroid Individuals” (Oral 13), on Thursday, October 31, 2019. Mouse studies have shown that the Thr92Ala-DIO2 polymorphism is associated with less anxiety and active exploration of new environments, but also with impaired memory and prolonged periods of immobility once the mice are settled. Ms. Peterson and her colleagues assessed mood, cognition, and health status among 134 adults, aged 21 to 70 years, who are receiving levothyroxine treatment for hypothyroidism. Patients with the Thr92Ala-DIO2 polymorphism showed better mood and health status and limited deficits in cognitive function.
  3. On Thursday, October 31, 2019, Dr. Maria Papaleontiou, of the University of Michigan, Ann Arbor, Michigan, will present the results of a retrospective, population-based cohort study assessing risks associated with thyroid hormone replacement. Dr. Papaleontiou and her colleagues used multivariable, generalized, linear mixed-effects regression models to identify correlates of incident atrial fibrillation and stroke among 756,555 thyroid hormone users with data in the Corporate Data Warehouse of the Veterans Health Administration from 2004 to 2017. They found that lower TSH levels were significantly associated with atrial fibrillation and stroke, suggesting the need for vigilance against thyroid hormone overreplacement. The presentation is titled, “Understanding the Risks of Thyroid Hormone Replacement: Is There a Relationship Between TSH Level and Atrial Fibrillation and Stroke?” (Oral 12).


The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community. ATA® is an international professional medical society with over 1,700 members from 70 countries around the world. Celebrating its 96th anniversary, the ATA® delivers its mission — transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community — through several key endeavors:

  • The publication of the highly regarded professional journals Thyroid®, Clinical Thyroidology®, and VideoEndocrinology
  • Annual scientific meetings
  • Biennial clinical and research symposia
  • Research grant programs for young investigators
  • Support of online professional, public, and patient educational programs
  • Development of guidelines for clinical management of thyroid disease and thyroid cancer

The ATA® promotes thyroid awareness and information through its online Clinical Thyroidology® for the Public (distributed free of charge to over 12,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA® website serves as a bonafide clinical resource for patients and the public who look for reliable information on the Internet.